Sherlock Biosciences
-
BioPharma, Devices & Diagnostics, SYN
Sherlock Biosciences secures $80M to bring molecular diagnostics to the home
Diagnostics developer Sherlock Biosciences has advanced its molecular diagnostic capabilities, which can now produce faster results on low-cost devices. The startup will use its Series B round of funding to expand the reach of its technology, potentially placing it directly in the hands of consumers around the world.
-
Sherlock, binx to develop point-of-care Covid-19 test using CRISPR technology
The Food and Drug Administration had previously granted an emergency use authorization for Abbott’s ID NOW point-of-care test, a decision for which the agency came under fire amid reports of the test delivering inaccurate results.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Feng Zhang’s Sherlock gets first-ever CRISPR nod as FDA green-lights Covid-19 test kit
The Cambridge, Massachusetts-based company, co-founded by CRISPR pioneer Feng Zhang, said Thursday that it had received an emergency use authorization for its SARS-CoV-2 test, which works by programming a CRISPR molecule to pick up the virus’ genetic signature.
-
Sherlock Biosciences raises $31M to apply CRISPR technology to diagnostics
The company aims to develop faster, lower-cost diagnostics using the gene-editing technology that could be used in oncology, infectious diseases, low-resource settings and other areas.